On June 2, 2020, Valisure Co-Founder & President David Light testified before the United States Senate Committee on Finance during the hearing titled: "COVID-19 and Beyond: Oversight of the FDA’s Foreign Drug Manufacturing Inspection Process."

In his remarks, Light addressed the urgent need for increased transparency and independent quality verification in the U.S. drug supply, particularly in light of global supply chain vulnerabilities and the ongoing COVID-19 crisis.

“At Valisure, our mission is to help ensure the safety, quality, and transparency of medications—and we do this with a very simple but novel approach: we check.” — David Light, Co-Founder & President, Valisure

Valisure is the first and only pharmacy in the United States that chemically batch-validates every medication it dispenses, using both proprietary technology and standard FDA assays. Headquartered at Yale Science Park in New Haven, Connecticut, Valisure is ISO-17025 accredited and registered with the FDA and DEA.

Light’s testimony highlighted several key issues:

• Over 80% of drug ingredients used in U.S. medications are manufactured overseas, primarily in India and China
• Valisure’s testing has shown that more than 10% of on-market medication batches fail to meet basic safety or quality standards
• Current FDA oversight relies heavily on self-reported data from overseas manufacturers, leaving room for error—and fraud
• The COVID-19 pandemic has only amplified risks tied to global drug sourcing and inspection delays

These findings underscore the critical need for independent chemical validation and stronger regulatory frameworks to ensure medication safety for American patients.

‍

Download the Full Oral Testimony →

Download the Full Written Testimony →

‍

The Opening Ceremony:

‍

Questions from Senator Grassley and answers from David Light: